                               SEQUENCE LISTING

<110> SANOFI 
      REGENERON PHARMACEUTICALS, INC.
 
<120> METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN 
      IL-4R ANTAGONIST

<130> 565201: SA9-134PC

<140>
<141>

<150> 62/077,669
<151> 2014-11-10

<150> 61/943,019
<151> 2014-02-21

<160> 8     

<170> PatentIn version 3.5

<210> 1
<211> 124
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic HCVR 
      polypeptide"

<400> 1
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Glu Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Arg Asp Tyr 
            20                  25                  30          


Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Ser Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Arg Leu Ser Ile Thr Ile Arg Pro Arg Tyr Tyr Gly Leu 
            100                 105                 110         


Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser 
        115                 120                 


<210> 2
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic LCVR 
      polypeptide"

<400> 2
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Ile Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Ser Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Phe Tyr Tyr Cys Met Gln Ala 
                85                  90                  95      


Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic HCDR1
      peptide"

<400> 3
Gly Phe Thr Phe Arg Asp Tyr Ala 
1               5               


<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic HCDR2
      peptide"

<400> 4
Ile Ser Gly Ser Gly Gly Asn Thr 
1               5               


<210> 5
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic HCDR3
      peptide"

<400> 5
Ala Lys Asp Arg Leu Ser Ile Thr Ile Arg Pro Arg Tyr Tyr Gly Leu 
1               5                   10                  15      


Asp Val 
        


<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic LCDR1
      peptide"

<400> 6
Gln Ser Leu Leu Tyr Ser Ile Gly Tyr Asn Tyr 
1               5                   10      


<210> 7
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic LCDR2
      peptide"

<400> 7
Leu Gly Ser 
1           


<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic LCDR3
      peptide"

<400> 8
Met Gln Ala Leu Gln Thr Pro Tyr Thr 
1               5                   


